PAIN THERAPEUTICS INC Form 8-K October 04, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISS Washington, D.C. 20549	SION	
Form 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the Securiti	es Exchange Act of 1934	
Date of Report (Date of earliest event Reporte	d): October 04, 2018	
Pain Therapeutics, Inc. (Exact Name of Registrant as Specified in Cha	arter)	
Delaware (State or Other Jurisdiction of Incorporation)	000-29959 (Commission File Number)	91-1911336 (I.R.S. Employer Identification Number)
7801 N Capital of Texas Highway, Suite 260,	Austin, TX 78731	
(Address of Principal Executive Offices) (Zip	Code)	
512-501-2444 (Registrant's telephone number, including area	a code)	
Not Applicable (Former name or former address, if changed si	ince last report)	
Check the appropriate box below if the Form 8 the registrant under any of the following provi	_	ltaneously satisfy the filing obligation of
[] Written communications pursuant to Rule 14a- [] Soliciting material pursuant to Rule 14a- [] Pre-commencement communications pursuant to Rule 14a- [] Pre-commencement to	12 under the Exchange Act (rsuant to Rule 14d-2(b) under	17 CFR 240.14a-12) the Exchange Act (17 CFR 240.14d-2(b))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company []	
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition beriod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []	

Item 7.01. Regulation FD Disclosure.

A copy of the investor presentation that Pain Therapeutics, Inc. used in conjunction with today's October 04, 2018 conference call is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit No. Description.

99.1 Pain Therapeutics, Inc. Investor presentation dated October 04, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pain Therapeutics, Inc.

Date: October 04, 2018 By: /s/ Remi Barbier

Remi Barbier

Chairman of the Board of Directors, President and Chief Executive Officer